Clinical trials: Depression in Adults
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Older Adults, Anxiety
Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery
Using a Hybrid Type 1 Effectiveness-Implementation randomized control trial (RCT) design, the investigators will test the effectiveness of a bundled behavioral activation and medication optimization in reducing symptoms of…
- Conditions
- Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy
- Trial name
- NCT05685511
- Testing
- Behavioral Activation, Medication Optimization, Usual care resources
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder
Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing
In this new research study, 80 adults aged > 60 years with a significant depressive disorder and slowed processing and/or gait speed will be randomized to receive levodopa (L-DOPA; which the Candidate has previously shown to…
- Trial name
- NCT04650217
- Testing
- Carbidopa/levodopa, Exercise training, Control
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Chronic Pain, Depression
A Behavioral Intervention for Depression and Chronic Pain in Primary Care
Chronic pain and depression frequently co-exist in late and mid-life and contribute to increased disability, high health care costs, psychiatric comorbidity, and suicide.
- Trial name
- Relief (NCT03265210)
- Testing
- RELIEF
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- Weill Medical College of Cornell University
Depression
Depression Prevention in Older Spousally-bereaved Adults
Using an indicated prevention approach, investigators propose to enroll 150 spousally-bereaved adults aged 60 years and older in the first 12 months after spousal death who are at high risk for major depression disorder because…
- Trial name
- WELL (NCT04016896)
- Testing
- WIdowed Elders' LIfestyle after Loss (WELL), Enhanced Usual Care
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU).
- Trial name
- NCT02634177
- Testing
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Where
- 23 sites in United States
- Volunteers
- 305 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Back Pain
Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
The following primary hypotheses will be tested: 1. During Step 1: Major Depressive Disorder (MDD) or Chronic Low Back Pain (CLBP) in < 40% of the initial 60 subjects treated with duloxetine (DUL) + Clinical Management(CM) during…
- Conditions
- Major Depressive Disorder, Back Pain, Aged
- Trial name
- ACHIEVE2 (NCT00696293)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Major Depressive Disorder
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible…
- Trial name
- NCT01441440
- Testing
- venlafaxine ER 75 mg/day (fixed dose), venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
- Where
- 63 sites in Japan
- Volunteers
- 538 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study.
- Trial name
- NCT01485887
- Testing
- Venlafaxine ER
- Where
- 25 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
A Long-Term Safety Study of ALKS 5461
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
- Trial name
- NCT02141399
- Testing
- ALKS 5461
- Where
- 158 sites in United States, Australia and 6 more
- Volunteers
- 1,485 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous…
- Trial name
- NCT01436175
- Testing
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
- Where
- 212 sites in United States, Canada and 12 more
- Volunteers
- 1,570 people
- Sponsor
- Shire
Weight Gain
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder…
- Trial name
- NCT00845507
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Cincinnati
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an…
- Trial name
- NCT03227224
- Testing
- JNJ-42847922
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC